Magic™ Humanized CD27 Immune Checkpoint Knock-In Mice

  • Check with publisher
  • Published date: September 30, 2019
    • Shirley, New York, United States
Magic™ Humanized CD27 Immune Checkpoint Knock-In Mice
Magic™ Humanized CD27 Immune Checkpoint Knock-In Mice

The activity of CD27 is restricted by the transient availability of its ligand CD70/TNFSF7, which is constitutively expressed on medullary thymic epithelial cells (mTECs) and dendritic cells. Apart from this, CD70/TNFSF7 is specifically expressed after immune activation, as it is found on activated DCs, B cells, conventional- and regulatory T cells and NK cells. The expression of CD70/TNFSF7 is exceedingly regulated by antigen since it is under control of PRRs, T cell and B cell antigen receptors, and its expression is further tuned by cytokines such as IL-1α, IL-12, TNFα, prostaglandin E2 and by CD28- and CD40 co-stimulation. Epithelial cells and other cell types may acquire CD70/TNFSF7 upon malignant transformation. The CD27 ligand CD70/TNFSF7 was similarly presented to promote TCR/CD3-induced proliferation of naive CD4+ and CD8+ human T cells as well as the generation of effector cells. https://www.creative-biolabs.com/drug-discovery/therapeutics/magic-humanized-cd27-immune-checkpoint-knock-in-mice.htm .

Result 0 votes
Jerry Carter
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Magic™ Humanized SIRPα Immune Checkpoint Knock-In Mice

    Magic™ Humanized SIRPα Immune Checkpoint Knock-In Mice

    Biology & Physiology Shirley (New York) September 30, 2019 Check with publisher

    In a wide variety of preclinical models, therapies that block the CD47/SIRPα axis stimulate phagocytosis of cancer cells in vitro and anti-tumor immune responses in vivo. Nowadays, many therapeutics targeting the CD47/SIRPα axis are under preclinical...

  • Magic™ Humanized CD28 Immune Checkpoint Knock-In Mice

    Magic™ Humanized CD28 Immune Checkpoint Knock-In Mice

    Biology & Physiology Shirley (New York) September 30, 2019 Check with publisher

    CD28 and CTLA4 are highly homologous and compete for the same ligands [B7-1 (CD80) and B7-2 (CD86)]. The affinity of CTLA4 binding to these ligands is higher than CD28, which enables CTLA4 to compete with CD28 for ligands and suppress effector T cell...

  • Magic™ Humanized CD137 Immune Checkpoint Knock-In Mice

    Magic™ Humanized CD137 Immune Checkpoint Knock-In Mice

    Biology & Physiology Shirley (New York) September 30, 2019 Check with publisher

    CD137 is one of the tumor necrosis factor (TNF) receptor family member, which is also known as TNFRSF9 and 4-1BB. CD137 is expressed on activated T cells, while to a larger extent on CD8+ than on CD4+ T cells. Additionally, CD137 is also found on den...